摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3H-2,1-Benzoxathiole | 272-18-4

中文名称
——
中文别名
——
英文名称
3H-2,1-Benzoxathiole
英文别名
——
3H-2,1-Benzoxathiole化学式
CAS
272-18-4
化学式
C7H6OS
mdl
MFCD18450489
分子量
138.19
InChiKey
XBHQQCZRNQGMEL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    34.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF<br/>[FR] ESTERS DE QUINUCLIDINE ET D'ACIDE 1-AZAHÉTÉROCYCLYLACÉTIQUE UTILISÉS COMME AGENTS ANTIMUSCARINIQUES, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS MÉDICINALES CORRESPONDANTES
    申请人:CHIESI FARMA SPA
    公开号:WO2013098145A1
    公开(公告)日:2013-07-04
    The invention relates to compounds of formula (I), wherein A, R1, R2, X, m and n are as defined in the specification, as selective M3 receptor antagonists, process for their preparation, composition comprising them and the therapeutic use thereof. Said compounds may be used in the treatment of, inter alia, a respiratory disease such as asthma and COPD.
    本发明涉及通式(I)的化合物,其中A、R1、R2、X、m和n如说明书中所定义,作为选择性M3受体拮抗剂,其制备方法,包含它们的组合物及其治疗用途。这些化合物可用于治疗,特别是呼吸系统疾病,如哮喘和慢性阻塞性肺病(COPD)。
  • QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF
    申请人:Chiesi Farmaceutici S.p.A.
    公开号:US20130172302A1
    公开(公告)日:2013-07-04
    Compounds of formula (I): wherein A, R1, R2, X, m, and n are as defined in the specification, are selective M3 receptor antagonists and may be used in the treatment of, inter alia, a respiratory disease such as asthma and COPD.
    式(I)化合物: 其中A、R1、R2、X、m和n如说明书中所定义,是选择性的M3受体拮抗剂,可用于治疗,包括但不限于,呼吸系统疾病,如哮喘和慢性阻塞性肺病(COPD)。
  • Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations
    申请人:The University of Chicago
    公开号:US10647733B2
    公开(公告)日:2020-05-12
    Metal-organic framework (MOFs) compositions based on nitrogen donor-based organic bridging ligands, including ligands based on 1,3-diketimine (NacNac), bipyridines and salicylaldimine, were synthesized and then post-synthetically metalated with metal precursors, such as complexes of first row transition metals. Metal complexes of the organic bridging ligands could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.
    基于以氮为供体的有机桥联配体,包括基于1,3-二酮亚胺(NacNac)、联吡啶柳酸亚胺属-有机框架(MOFs)组成物被合成,然后用属前驱体如第一行过渡属的络合物进行后合成属化。有机桥联配体属络合物也可以直接并入MOFs中。MOFs提供了一个多功能的、可回收和可重复使用的单点固体催化剂家族,用于催化各种不对称有机转化。这些固体催化剂也可以集成到流动反应器或超临界流体反应器中。
  • [EN] GLYCINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE GLYCINE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
    申请人:CHIESI FARMA SPA
    公开号:WO2012069275A1
    公开(公告)日:2012-05-31
    The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.
    本发明涉及作为肌碱受体拮抗剂的生物碱酯衍生物,其制备方法,包含它们的组合物以及它们的治疗用途。
  • GLYCINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF
    申请人:AMARI Gabriele
    公开号:US20120134934A1
    公开(公告)日:2012-05-31
    Alkaloid aminoester derivatives according to formula (I) and (VI) act as muscarinic receptor antagonists.
    生物碱酯衍生物根据式(I)和(VI)作为肌碱受体拮抗剂。
查看更多

同类化合物

四碘-2-磺基苯酸酐 四溴-2-磺基苯甲酸环酐 N,N'-二[[(1,3-苯并氧硫杂环戊烷-2-基)硫代]甲基]脲 5-羟基-4,6,7-三甲基-2-丙基-1,3-苯并氧杂噻唑 3-(5-羟基-4,6,7-三甲基-1,3-苯并氧杂噻唑-2-基)丙醇 2-磺基苯甲酸酐 2-(2-甲氧基丙烷-2-基)-7,7-二甲基-4-叔-丁基-8-氧杂-9-硫杂双环[4.3.0]壬-2,4,10-三烯 1,3-苯并噁噻唑,5-甲氧基-,3,3-二氧化 3-ethoxycarbonyl-2-methyl-5-(2',3'-O-sulfonyl-β-D-erythrofuranosyl)furan 2-Isopropyloxy-2-n-pentyl-1,3-benzoxathiol 5-nitrospiro[1,3-benzoxathiole-2,1'-cyclohexane] 2-ethyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 4-methyl-2-sulfo-benzoic acid-anhydride 2-heptyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 2-butyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 2-hexyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 1,1-dichloro-3,3-bis(trifluoromethyl)-5-methyl-2,1(3H)-benzoxathiole 4-(2-Cyclohexyl-benzo[1,3]dithiol-2-yl)-2-(2-p-tolyl-benzo[1,3]oxathiol-2-yl)-1H-pyrrole 2-Methoxy-4,5-methylenethiooxyamphetamine 2-Nonyl-benzo[1,3]oxathiole 2-t-Butyloxy-2-t-butyl-1,3-benzoxathiol 6-tert-Butyl-2-methyl-4-oxo-4H-3,1-benzoxathiin-8-carboxamid tert-butyl (3-((6-acetylbenzo[d][1,3]oxathiol-5-yl)oxy)propyl)carbamate 5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-4H-benzo[d][1,3]oxathiin-4-one 2,10-dimethyl-dibenz[c,e][1,2,7]oxadithiepin-5,5,7,7-tetraoxide 8-Trimethylsilyl-2,2,6,6-tetramethylbenzo[1,2-d:5,4-d']-bis(1,3)oxathiole 5-fluoro7-(2-chloro-phenyl)-benzo[1,3]oxathiole-2,2-dicarboxylic acid diethyl ester 1-(2,3,7,8-Tetrahydro-benzo[1,2-b;4,5-b']bis[1,4]dithiin-5-yl)-ethanone 1,1-Dioxo-5-propoxy-1H-1λ6-benzo[c][1,2]oxathiol-3-one 7-<1-methyl-1-(trimethylamonio)ethyl>-3,3-dimethyl-3H-2,1-benzoxiathiole 1,1-dioxide fluorosulfonate 3-(5-methoxymethoxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propanol Benzo<1,2-c:5,4-c'>1,2,6,7-diisooxathiol-3,5-dion-1,1,7,7-tetroxid 2,3,4,5,7,8-Hexachlorbicyclo<4.2.0>octa-1,3,5-trien-7,8-diylsulfat 4-methyl-3,3-bis(trifluoromethyl)-3',3'-dimethyl-1,1'-spiro<3H-2,1-benzoxathiole> 5,7-diisopropyl-3,3-dimethylbenz-2,1-oxathiole 1-oxide 6-fluoro-5-methoxy-1,3-benzoxathiole 3,3-dioxide 3-ethoxycarbonyl-2-methyl-5-(2',3'-O-sulfonyl-α-D-erythrofuranosyl)furan 5-Isopropoxy-1,1-dioxo-1H-1λ6-benzo[c][1,2]oxathiol-3-one 1,3-Benzoxathiol-essigsaeure-(2)-methylester 2-Hydroxy-3-methyl-benzo-1,4-oxathien 4-(5-chloro-1,4-benzoxathian-8-oyl)-5-cyclopropylisoxazole S-oxide 5-Chlor-1,3-benzoxathiol 3-(3-benzyloxy-4-methoxyphenyl)-2,3-dihydro-1,4-benzoxathiine 2-(2-Cyclohexyl-benzo[1,3]oxathiol-2-yl)-1-methyl-1H-pyrrole 2,2'-spirobi(1,3-benzoxathiole) 1-(2-phenyl-benzo[1,3]oxathiol-2-yl)-propan-2-ol 2-Methyl-benzo-1,4-oxathiadien